Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
|Webcasts|June 18, 2020
Preformulation of Small Molecule Drugs
Author(s)Pace Analytical Sciences
Preformulation studies play a significant role in developing approaches to analytical and formulation development based on the physicochemical properties of small-molecule pharmaceuticals. This webinar will provide insights into the preformulation phase of drug development and will illustrate common issues encountered. Live: Thursday, Jun. 18, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after final airing Jun. 18, 2021 Register free
Register free:
Event Overview:
Preformulation studies play a significant role in developing approaches to analytical and formulation development based on the physicochemical properties of small-molecule pharmaceuticals. Data collected during pre-formulation informs:
- Dosage form selection and design
- Excipient choice
- Understanding of the feasibility of drug product development
- Regulatory strategies
This webcast will provide insights into the preformulation phase of drug development and will illustrate common issues encountered.
Key Learning Objectives:
- To identify the typical experiments performed in preformulation of small molecules
- To recognize how physicochemical properties will affect the choice of dosage form
- To spot potential formulation issues that could have been prevented by pre-formulation activities
Speaker: Frank Koppenhagen, Ph.D., Vice President, Pharmaceutical Development, Pace Analytical Life Sciences
Time and Date: Thursday, Jun. 18, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
On demand available after final airing Jun. 18, 2021
Sponsor: Pace Analytical Sciences
Register free:
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Trending on Pharmaceutical Technology
1
Pharma Fundamentals: Digital Pathology in Drug Development, Part 1
2
PharmTech’s Weekly Roundup—September 25, 2026
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
5